Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Keith Berman, MPH, MBA

Keith Berman, MPH, MBA, Consultant, Health Research Associates Consultant
Health Research Associates
Member of the Healthcare Council

Keith Berman, MPH, MBA, founded Health Research Associates in 1996. HRA provides reimbursement consulting, business development and market research services to leading biopharmaceuticals, blood products and medical device manufacturers and suppliers. Previously, Mr. Berman worked for ten years in product development, reimbursement development, and market research roles at Baxter Healthcare, Siemens Medical, and MiniMed Technologies (now a Medtronic division). Since 1989, he has also served as editor of International Blood/Plasma News, an blood products industry newsletter. (This is me - Update Profile)


Employment History
1996 - present Consultant
Health Research Associates

GLG Study Groups with Keith Berman, MPH, MBA(?)

Study Group Name Members
Economic Experts on Managed Care 630
Medicare Experts 429

GLG NewsSM Analyses by Keith Berman, MPH, MBA(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Cerberus Reportedly Shopping Talecris Biotherapeutics to Competitors | 06-13-2008
Analysis of: Owners Might Sell Talecris Instead of Pursuing an IPO | www.newsobserver.com
Author: Keith Berman, MPH, MBA, Consultant, Health Research Associates

After abandoning a 2007 IPO, Talecris majority owner Cerberus Capital is now reported to be pursuing negotiations to sell the $1.2 billion plasma products firm. Talecris' valuation will necessarily involve projections of worldwide market demand for intravenous immunoglobulin (IVIg), the industry's most...

Cerberus May Be Looking to Sell Talecris Biotherapeutics | 06-11-2008
Analysis of: Cerberus eyes Talecris sale instead of IPO | www.ft.com
Author: Keith Berman, MPH, MBA, Consultant, Health Research Associates

If a report in the Financial Times is credible, the already consolidating plasma products industry could render down to even fewer players in the near future with the sale of Talecris to a major competitor. The value of the company will be strongly influenced by the direction in demand for its industry's...

FDA Explodes ZymoGenetics' Recothrom Safety Argument | 05-09-2008
Analysis of: FDA Asks ZymoGenetics to Revise New Product's Press Release | seattletimes.nwsource.com
Author: Keith Berman, MPH, MBA, Consultant, Health Research Associates

The FDA -- likely with encouragement of King Pharmaceuticals -- has ordered ZymoGenetics to cease dissemination of materials that cite "a significantly lower incidence of antibody formation compared to the commercially available bovine thrombin product [Thrombin-JMI]." "This statement is false or misleading...

Startling New Evidence Suggests IVIg May Help Alzheimer's Patients | 04-18-2008
Analysis of: Study Suggests Gammagard Liquid May Target the Primary Pathway Involved in Alzheimer's Disease | biz.yahoo.com
Author: Keith Berman, MPH, MBA, Consultant, Health Research Associates

Three presentations at this week's AAN meeting in Chicago are adding in a big way to accumulating evidence that intravenous immunoglobulin (IVIg) may slow, halt or even PREVENT accumulation of toxic beta-amyloid -- a prime culprit in the development of Alzheimer's disease (AD) in millions of aging individuals....

View All GLG News SM Analyses by Keith Berman, MPH, MBA

GLG InstituteSM Seminars with Keith Berman, MPH, MBA(?)

 
Keith Berman, MPH, MBA has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Keith Berman, MPH, MBA









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-09-06T21:45:17.077